Background {#Sec1}
==========

Type 2 diabetes mellitus (T2DM) greatly increases the risks of cardiovascular disease (CVD) and heart failure \[[@CR1]--[@CR3]\]. Especially, left ventricular diastolic dysfunction, which develops early in T2DM, is an important factor in the onset and exacerbation of heart failure \[[@CR4]--[@CR6]\]. T2DM has been shown to cause left ventricular dysfunction independently of glycemic control, hypertension, and coronary artery disease \[[@CR7], [@CR8]\], and its pathogenic mechanism involves enhanced oxidative stress and chronic inflammation, which accompanies hyperglycemia \[[@CR9], [@CR10]\]. However, glycemic control in those using anti-diabetic drugs was not found to be effective in improving left ventricular diastolic function \[[@CR11]\]. Small-scale studies showed that dipeptidyl peptidase (DPP)-4 inhibitors and thiazolidinediones (TZD) were effective in improving left ventricular diastolic function \[[@CR12], [@CR13]\], but larger clinical studies showed exacerbation of heart failure with the use of such agents \[[@CR14], [@CR15]\]. The combined effect of factors such as aging, plasma glucose values, hypertension, and obesity might be partially responsible for the lack of an effective therapy for left ventricular diastolic dysfunction \[[@CR4], [@CR5], [@CR8]\].

Recently, empagliflozin and canagliflozin, which are sodium-glucose cotransporter 2 (SGLT2) inhibitors, were reported to reduce all-cause mortality, cardiovascular mortality, and hospitalization due to heart failure in T2DM \[[@CR16]--[@CR19]\]. However, it is not clear yet how SGLT2 inhibitors reduced hospitalizations due to heart failure, which was shown in the early period of the EMPA-REG and CANVAS trials \[[@CR16], [@CR18]\]. Furthermore, the effect of SGLT2 inhibitors on left ventricular diastolic function has not been elucidated.

We have performed the first prospective study of the effects of canagliflozin on left ventricular diastolic function in patients with T2DM.

Methods {#Sec2}
=======

Study participants {#Sec3}
------------------

This prospective single-center pilot study was performed to evaluate the effects of additional treatment with canagliflozin on left ventricular function in T2DM. Between July 2017 and December 2017, 38 diabetic patients who had inadequately controlled T2DM were consecutively recruited from outpatients at Tsuruoka Kyoritsu Hospital, Yamagata, Japan. All participants were evaluated at baseline and at 3 months after beginning additional treatment with canagliflozin. During the 6 months before the start of this study and the 3 months after the start of this study, participants had not changed their use of antidiabetic drugs or any other drugs that could affect glucose metabolism such as renin--angiotensin--aldosterone system (RAAS) inhibitors (angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers), beta blockers, diuretics, and statins. The inclusion criteria were as follows: (1) T2DM with HbA1c (NGSP) of ≥ 7.0%, \< 10.5% and (2) experiencing no changes in antidiabetic drugs or any other drugs during the 6 months prior to the start of this study. Inclusion criteria also included (3) satisfaction of either (a) or (b) as follows: (a) age ≥ 45 and \< 75 years without a history of CVD and with ≥ 2 of the following risk factors determined at the screening visit: duration of T2DM ≥ 10 years, systolic blood pressure (SBP) ≥ 140 mmHg (average of 3 readings at screening visit), taking at least one anti-hypertensive agent, current daily cigarette smoker (Brinkmann index ≥ 200), microalbuminuria or macroalbuminuria (microalbuminuria: urinary albumin excretion from 30 to 300 mg/g Cr; macroalbuminuria: urinary albumin excretion of ≥ 300 mg/g Cr); dyslipidemia (abnormal values for ≥ 1 among high-density lipoprotein \[HDL\] cholesterol \< 40 mg/dL, low-density lipoprotein (LDL) cholesterol ≥ 120 mg/dL, and/or triglycerides (TG) ≥ 150 mg/dL); carotid intima media thickness ≥ 1.1 mm, and plaque positive; or (b) age ≥ 35 and \< 75 years with a history of ≥ 1 of the following indicating CVD: old cerebral infarction, old myocardial infarction, hospital admission for unstable angina, chronic heart failure, coronary artery bypass graft, percutaneous coronary intervention (with or without stenting), peripheral revascularization (angioplasty or surgery), symptomatic with documented hemodynamically significant carotid or peripheral vascular disease, or amputation secondary to vascular disease. Patients were excluded based on: (1) age \< 35 years or ≥ 75 years; (2) taking antipsychotics; (3) arrhythmia; (4) severe renal dysfunction (serum Cr ≥ 2.5 mg/dL); (5) severe liver dysfunction (3× upper limit of normal); (6) diabetic ketosis or diabetic coma; (7) insulin-dependent diabetes mellitus; (8) malignancy, or (9) acute heart failure or acute myocardial infarction. All participants underwent blood tests, including those for fasting plasma glucose, HbA1c, estimated glomerular filtration rate (eGFR), HDL cholesterol, LDL cholesterol, TG, brain natriuretic peptide (BNP), hemoglobin (Hb), and hematocrit (Hct). Clinical data (duration of diabetes; body mass index \[BMI\]; SBP; diastolic blood pressure \[DBP\]; heart rate \[HR\]; history of CVD; insulin therapy; and use of oral anti-diabetic drugs, anti-hypertensive agents, and lipid-lowering agents) were obtained from medical records and a questionnaire.

Thirty-seven patients were included in the analysis after excluding 1 with arrhythmias.

The study protocol was approved by the ethics committee of Tsuruoka Kyoritsu Hospital (approval number: 2017-01; date: 7th June, 2017), and the study was conducted according to the principles of the Helsinki Declaration II. This study was registered at the UMIN Clinical Trial Registry (UMIN000028141). All patients were informed of the purpose of the study after which consent was obtained.

Analysis of echocardiographic findings {#Sec4}
--------------------------------------

Standardized transthoracic and Doppler echocardiographic examinations were performed in all participants using commercially available equipment (iE33, Philips, Amsterdam, Netherlands). Left atrial diameter and end-diastolic and end-systolic left ventricular internal diameters were measured on a 2-dimensional guided M-mode recording. Left ventricular ejection fraction (EF) was assessed by the modified Simpson's Biplane Method. Using two-dimensional echocardiograms the left ventricular mass index was determined by the area-length method \[[@CR20]\]. To assess diastolic function, the following mitral pulse wave Doppler and tissue Doppler parameters were measured: peak early (E) and late (A) diastolic filling velocities, E/A ratio, deceleration time of E wave (DT), septal early diastolic mitral annular tissue velocity (septal e′), and lateral early diastolic mitral annular tissue velocity (lateral e′). We also calculated the E/e′ ratio by dividing the transmitral E peak by e′ \[[@CR21]\].

Assessment of baroreflex sensitivity (BRS) {#Sec5}
------------------------------------------

Using the spontaneous sequence method, the beat-to-beat BP was measured for 15 min after 15 min of supine rest as the slope of the relationship between spontaneous changes in SBP and the pulse interval. Measurement was made using the second and third fingers of the right hand by the vascular unloading technique (Task Force Monitor, CNSystems, Graz, Austria). For calculation of BRS, the relative changes in SBP (mmHg) and the R--R interval (msec), which is expressed as the distance between corresponding QRS complexes, were considered according to the sequence method with cut-off points of 1 mmHg and 3 ms, respectively \[[@CR22]\].

Assessment of heart rate variability (HRV) {#Sec6}
------------------------------------------

A 3-lead ECG with a sampling frequency of 1000 Hz was recorded for 15 min after the participant had rested for 15 min. The HRV was calculated during the test and included all recorded R--R intervals. HRV was calculated by the frequency domain method using a power spectral analysis of rhythmic oscillations of the R--R interval. The relative contributions of the low frequency (LF) power (0.04--0.15 Hz), high frequency (HF) power (0.15--0.4 Hz), and very-low-frequency (VLF) power (0--0.04 Hz) to total power were calculated as follows: *LF normalized units (LFnu%) *=* LF absolute power* (ms^2^)*/total power* (ms^2^)* − VLF power* (ms^2^)×100 *and HFnu% *=* HF absolute power* (ms^2^)*/total power* (ms^2^)* − VLF* (ms^2^)×100. The LFnu%/HFnu% ratio was considered to indicate sympathetic/vagal tone. All calculations were performed using the Task Force Monitor (CNSystems, Graz, Austria) \[[@CR23]\].

Study outcome {#Sec7}
-------------

The primary study outcome was a change in the septal E/e\` as a parameter of left ventricular diastolic function. Secondary endpoints included changes in the following variables at the end of the 12-week treatment relative to the baseline: (1) echocardiographic parameters: left atrial diameter, left ventricular end-diastolic diameter, left ventricular end-systolic diameter, EF, left ventricular mass index, E, A, E/A, DcT, septal e′, lateral e′, and lateral E/e′; (2) autonomic function: BRS and LF/HF; (3) glycemic control variables: fasting plasma glucose and HbA1c level; (4) lipid metabolism variables: TG, LDL cholesterol, and HDL cholesterol; (5) BMI; (6) SBP and DBP, (7) HR; (8) BNP; (9) Hb and Hct; and (10) eGFR.

Sample size and statistical analyses {#Sec8}
------------------------------------

Because there has been no report on the effect of SGLT-2 inhibitors to improve the septal E/e′, we used information from a previous report on the effect of another drug on the septal E/e′ (approximately a 1.5 reduction) to estimate the required sample size \[[@CR12]\]. Sample size estimates were based on the following: standard deviation, 3; α-level, 0.05; and power, 80%. Sample size was estimated to be 33 people. Assuming a dropout rate of 10%, the target number of patients was therefore set at 38 patients.

Data analyses were performed using the Statistical Package for the Social Sciences 22.0 software (IBM, Armonk, NY, USA). Patients' characteristics and results are presented as mean ± SD, mean ± standard error, or median with interquartile range (IQR) as appropriate according to the data distribution. Comparison of variables between baseline and 3 months after treatment were made using the paired *t* test or Wilcoxon signed-rank test (Table [2](#Tab2){ref-type="table"}). Pearson's correlation analysis or Spearman's rank correlation coefficient test was used for single correlations (Table [3](#Tab3){ref-type="table"}). Multiple-linear regression was used to assess individual and cumulative effects of ΔHb, age, sex, SBP, eGFR, and HR on the Δseptal E/e′ ratio. Independent variables were selected among variables that were significantly correlated with the Δseptal E/e′ ratio (Table [4](#Tab4){ref-type="table"}). The delta (∆) values for BRS and LF/HF were calculated according to values at 3 months after treatment-value at baseline. All other delta values were calculated as \[(value at 3 months after treatment-value at baseline) × 100\]/value at baseline (%). As shown in Fig. [2](#Fig2){ref-type="fig"} and Table [5](#Tab5){ref-type="table"}, the baseline septal E/e′ ratio was divided into tertiles (T1 \< 12, T2 ≥ 12- \< 16, T3 ≥ 16). The Jonckheere trend test was used to test for linear trends in Δseptal E/e′ ratio in relation to baseline septal E/e′ ratio tertiles. The analysis of variance (ANOVA) was used to compare Δseptal E/e′ ratios among participants with various baseline septal E/e′ ratio tertiles. In ANOVA, the Tukey post hoc test was also used to compare Δseptal E/e′ ratios among different baseline septal E/e′ ratio groups. As shown in Table [6](#Tab6){ref-type="table"}, the effects of canagliflozin on Δseptal E/e′ ratios were analyzed for the following subgroups: sex, history of hypertension, presence of CVD, insulin use, sulfonylurea use, metformin use, DPP-4 inhibitor use, calcium channel blocker use, RAAS inhibitor use, beta blocker use, and diuretic use. In the subgroup analysis, mean Δseptal E/e′ was compared using Student's *t* test. Hypertension was defined as follows: SBP ≥ 140 mmHg, DBP ≥ 90 mmHg and/or the use of at least one anti-hypertensive agent. CVD was considered to be present if any of the following had occurred: cerebral infarction, myocardial infarction, hospital admission for unstable angina, heart failure, coronary artery bypass graft, percutaneous coronary intervention (with or without stenting), peripheral revascularization (angioplasty or surgery), symptoms consistent with documented hemodynamically significant carotid or peripheral vascular disease, and/or amputation secondary to vascular disease. As shown in Additional file [1](#MOESM1){ref-type="media"}: Table S1, participants were divided into a primary prevention group without a history of CVD, a secondary prevention group with a history of CVD, and an overall population group. In each group, comparison of variables between baseline and 3 months after treatment were made using the paired *t* test. The Student's *t* test was used to compare mean Δseptal E/e′ in the primary prevention group and secondary prevention group. A *p* value \< 0.05 was considered significant.

Results {#Sec9}
=======

Baseline characteristics of study participants {#Sec10}
----------------------------------------------

A total of 37 patients (25 males and 12 females) were included in the analysis. Table [1](#Tab1){ref-type="table"} shows the baseline clinical, anthropometric, and pharmacologic data on the study participants. Mean age of participants was 64.2 ± 8.1 years (mean ± SD), mean duration of diabetes was 13.5 ± 8.1 years, and mean HbA1c was 7.9 ± 0.7%. Of the participants, 86.5% had hypertension, 100% had dyslipidemia, and 32.4% had CVD. At baseline, 32.4% of patients were on insulin, 37.8% on sulfonylureas, 54.1% on metformin, 43.2% on DPP-4 inhibitors, 45.9% on calcium-channel blockers, 45.9% on RAAS inhibitors (angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers), 13.5% on beta blockers, 10.8% on diuretics, 48.6% on statins, and fibrates on 2.7%.Table 1Baseline characteristics of the study populationAge, (years)64.2 ± 8.1No. patients37Sex, male/female25/12Duration of diabetes, (years)13.5 ± 8.1BMI, (kg/m^2^)27.1 ± 4.6Fasting plasma glucose, (mg/dL)146.3 ± 28.8HbA1c, (%)7.9 ± 0.7Hypertension, n (%)32 (86.5)Dyslipidemia, n (%)37 (100)History of cardiovascular disease, n (%)12 (32.4)Oral anti-diabetic drugs, n (%)34 (91.9) Insulin, n (%)12 (32.4) Sulfonylureas, n (%)14 (37.8) Glinides, n (%)1 (2.7) Metformin, n (%)20 (54.1) Thiazolidinediones, n (%)5 (13.5) DPP-4 inhibitors, n (%)16 (43.2) GLP-1 receptor agonists, n (%)2 (5.4) α-glucosidase inhibitors, n (%)10 (27)Anti-hypertensive agents, n (%)25 (67.6) Calcium channel blockers, n (%)17 (45.9) RAAS inhibitors, n (%)17 (45.9) Beta blockers, n (%)5 (13.5)Diuretics, n (%)4 (10.8)Lipid-lowering agents, n (%)18 (48.6) Statins, n (%)18 (48.6) Fibrates, n (%)1 (2.7)Values are mean ± SD or no. (%)*BMI* body mass index; *DPP* dipeptidyl peptidase-4; *GLP* glucagon-like peptide; *RAAS* renin--angiotensin--aldosterone system

Comparison of values from baseline to after 3 months {#Sec11}
----------------------------------------------------

Compared to baseline levels, decreases were found at 3 months in mean fasting plasma glucose (146.3 ± 28.8 mg/dL to 125.9 ± 24.6 mg/dL, *p* = 0.001), mean HbA1c (7.9 ± 0.7% to 7.1 ± 0.6%, *p* \< 0.001), mean SBP (134.1 ± 14.3 mmHg to 130.3 ± 15.1 mmHg, *p* = 0.028), mean left ventricular mass index (82.0 ± 15.8 g/m^2^ to 77.3 ± 16.4 g/m^2^, *p *= 0.003), mean septal E/e′ ratio (13.7 ± 3.5 to 12.1 ± 2.8, *p* = 0.001), and mean lateral E/e′ ratio (9.7 ± 2.9--8.3 ± 1.9, *p* \< 0.001). Increases after 3 months of treatment were identified in mean Hb (13.9 ± 1.2 g/dL to 14.7 ± 1.4 g/dL, *p* \< 0.001) and mean Hct (40.7 ± 3.3% to 44.0 ± 3.7%, *p* \< 0.001). There were no differences from baseline values to the end of the 3-month treatment period in median BNP (11.4 \[IQR 9.1--20.6\] pg/mL to 10.6 \[IQR 6.3--15.8\] pg/dL, *p* = 0.061), mean EF (65.7 ± 5.0% to 65.3 ± 5.5%, *p* = 0.652), median BRS (9.6 \[IQR 6.3-12.5\] ms/mmHg to 7.9 \[IQR 5.4--11.4\] ms/mmHg, *p* = 0.592), and median LF/HF (1.3 \[IQR 0.9--2.3\] to 1.2 \[IQR 0.7--2.0\], *p *= 0.202) (Fig. [1](#Fig1){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}).Fig. 1Figure title: Septal E/e′ ratio, left ventricular mass index, EF, heart rate, baroreflex sensitivity, and LF/HF at baseline (pre-canagliflozin) and at the 3-month follow-up (post-canagliflozin). Data are mean ± SD or median (25th--75th percentiles). *E* velocity of early mitral flow; *e′*, early peak velocity of septal annulus; *LVMI* left ventricular mass index; *EF* ejection fraction; *BRS* baroreflex sensitivity; *LF/HF* low frequency/high frequency; *SD* standard deviation; *IQR* interquartile range Table 2Comparison of variables between baseline and 3 months after treatmentVariablesPre canagliflozinPost canagliflozin*p* valueFasting blood glucose (mg/dL)146.3 ± 28.8125.9 ± 24.60.001HbA1c (%)7.9 ± 0.77.1 ± 0.6\< 0.001BMI (kg/m^2^)27.1 ± 4.626.5 ± 4.3\< 0.001Blood pressure (mmHg) Systolic134.1 ± 14.3130.3 ± 15.10.028 Diastolic80.8 ± 9.981.4 ± 9.50.627Heart rate (beats/min)74.8 ± 8.974.8 ± 9.20.984Lipid profile (mg/dL) Triglycerides146 (101--190)114 (85--148)\< 0.001 LDL cholesterol111.2 ± 32.7113.9 ± 31.00.516 HDL cholesterol47.9 ± 10.553.9 ± 11.9\< 0.001eGFR (mL/min/1.73 m^2^)76.1 ± 19.571.4 ± 16.90.001BNP (pg/mL)11.4 (9.1--20.6)10.6 (6.3--15.8)0.061Hemoglobin (g/dL)13.9 ± 1.214.7 ± 1.4\< 0.001Hematocrit (%)40.7 ± 3.344.0 ± 3.7\< 0.001Echocardiographics Left atrial diameter (mm)36.4 ± 5.336.5 ± 5.20.789 LV end-diastolic diameter (mm)47.8 ± 5.447.2 ± 4.80.253 LV end-systolic diameter (mm)31.2 ± 5.130.5 ± 4.00.226 EF (%)65.7 ± 5.065.3 ± 5.50.652 LV mass index (g/m^2^)82.0 ± 15.877.3 ± 16.40.003 E (m/s)0.7 ± 0.10.6 ± 0.10.013 A (m/s)0.9 ± 0.20.2 ± 0.20.053 E/A0.8 ± 0.20.8 ± 0.20.446 DcT (ms)265.5 ± 53.4276.2 ± 58.00.298 Septal e′ (cm/s)5.3 ± 1.25.4 ± 1.20.294 Lateral e′ (cm/s)7.5 ± 1.67.8 ± 1.60.097 Septal E/e′ ratio13.7 ± 3.512.1 ± 2.80.001 Lateral E/e′ ratio9.7 ± 2.98.3 ± 1.9\< 0.001Autonomic function BRS (s/mmHg)9.6 (6.3--12.5)7.9 (5.4--11.4)0.592 LF/HF1.3 (0.9--2.3)1.2 (0.7--2.0)0.202Data are mean ± SD or median (25th--75th percentiles)*BMI* body mass index; *LDL* low density lipoprotein; *HDL* high density lipoprotein; *eGFR* estimated glomerular filtration rate; *BNP* brain natriuretic peptide; *LV* left ventricular; *EF* ejection fraction; *E* velocity of early mitral flow; *A* velocity of late mitral flow; *DcT* deceleration time of early mitral inflow; *e′* early peak velocity of annulus; *BRS* baroreflex sensitivity; *LF/HF* low frequency/high frequency

Univariate correlates of changes in the septal E/e′ ratio {#Sec12}
---------------------------------------------------------

Correlation analysis showed that the Δseptal E/e′ ratio was correlated with the baseline septal E/e′ ratio (*r* = − 0.618, *p* = 0.000), age (*r* = − 0.464, *p* = 0.004), baseline SBP (*r* = − 0.335, *p* = 0.042), baseline HR (*r* = 0.359, *p* = 0.029), baseline eGFR (*r* = 0.355, *p* = 0.031), and ΔHb (*r* = − 0.496, *p* = 0.002) (Table [3](#Tab3){ref-type="table"}).Table 3Univariate correlates of change in septal E/e′ ratio vs. baseline and change in variablesVariablesΔseptal E/e′ vs. baseline variablesΔseptal E/e′ vs. Δvariables*rprp*Age (years)− 0.4640.004----Duration of diabetes (years)0.0210.902----Septal E/e′ ratio− 0.618\< 0.001----LV mass index (g/m^2^)− 0.2520.133− 0.1580.351BMI (kg/m^2^)− 0.0540.7530.0340.840Fasting plasma glucose (mg/dL)− 0.0090.960− 0.2770.097HbA1c (%)− 0.0090.957− 0.0600.725SBP (mmHg)− 0.3350.0420.0660.699DBP (mmHg)− 0.0220.899− 0.0920.588Heart rate (beats/min)0.3590.029− 0.2230.184BNP (pg/mL)0.0740.665− 0.0840.623Hemoglobin (g/dL)0.0920.588− 0.4960.002Hematocrit (%)0.0950.575− 0.2650.112eGFR (mL/min/1.73 m^2^)0.3550.0310.0160.924Triglycerides (mg/dL)− 0.1150.497− 0.1590.346LDL cholesterol (mg/dL)0.0360.833− 0.0840.621HDL cholesterol (mg/dL)0.1240.4630.0390.819BRS (s/mmHg)0.2320.1670.2660.111LF/HF0.2110.211− 0.3220.052The delta (Δ) values for baroreflex sensitivity, and LF/HF were calculated as values at 3 months after treatment-value at baseline. All other delta values were calculated as \[(value at 3 months after treatment − value at baseline) × 100\]/value at baseline (%)*E* velocity of early mitral flow; *e′* early peak velocity of annulus; *LV* left ventricular; *BMI* body mass index; *SBP* systolic blood pressure; *DBP* diastolic blood pressure; *BNP* brain natriuretic peptide; *eGFR* estimated glomerular filtration rate; *LDL* low density lipoprotein; *HDL* high density lipoprotein; *BRS* baroreflex sensitivity; *LF/HF* low frequency/high frequency

Multivariate analysis of changes in the septal E/e′ ratio {#Sec13}
---------------------------------------------------------

Multiple regression analysis showed that ΔHb were inversely related to the Δseptal E/e′ ratio. These findings remained after adjusting the Δseptal E/e′ ratio for age, sex, SBP, eGFR, and HR (Table [4](#Tab4){ref-type="table"}).Table 4Multiple regression analysis of changes in the septal E/e′ ratioIndependent variablesModel 1Model 2Model 3*βpβpβp*ΔHemoglobin (g/dL)− 0.3570.024− 0.3740.017− 0.4240.005Age (years)− 0.2660.086− 0.1920.238− 0.1740.244Sex (male/female)− 0.1950.186− 0.2650.063− 0.2660.049SBP (mmHg)− 0.1860.206eGFR (mL/min/1.73 m^2^)0.1880.213Heart rate (beats/min)0.3110.024Dependent variable was Δ septal E/e′, and the independent variables were Model 1, Model 2, and Model 3. Model 1: Δhemoglobin, age, sex, and SBP; Model 2: Δhemoglobin, age, sex, and eGFR; Model 3: Δhemoglobin, age, sex, and heart rate. Model 1: R-squared 0.420, adjusted R-squared 0.348; Model 2: R-squared 0.419, adjusted R-squared 0.347; Model 3: R-squared 0.481, adjusted R-squared 0.416*E* velocity of early mitral flow; *e′* early peak velocity of septal annulus; *SBP* systolic blood pressure; *eGFR* estimated glomerular filtration rate

Comparison of changes in the septal E/e′ ratio with the baseline septal E/e′ ratio {#Sec14}
----------------------------------------------------------------------------------

Figure [2](#Fig2){ref-type="fig"} and Table [5](#Tab5){ref-type="table"} show the comparisons of Δseptal E/e′ ratio among participants with various baseline septal E/e′ ratios according to tertiles based on ANOVA. There was a significant difference in Δseptal E/e′ ratios among these three groups. The results were then analyzed by the Tukey post hoc test. The T2 (*p* = 0.03) and T3 (*p* = 0.009) groups had decreased septal E/e′ ratios in comparison with the T1 group. This observation was confirmed by the Jonckheere trend test: Δseptal E/e′ ratio (*p* = 0.008) was significantly correlated with tertiles of baseline septal E/e′ ratios.Fig. 2Comparison of changes in septal E/e′ ratio with baseline septal E/e′ ratio based on ANOVA. Changes in the septal E/e′ ratio divided according to baseline septal E/e′ ratio tertiles. Tukey post hoc test compared with T1. *E* velocity of early mitral flow; *e′* early peak velocity of septal annulus Table 5Comparison of Δseptal E/e′ ratios with baseline septal E/e′ ratios based on ANOVABaseline septal E/e′ ratio tertilesT1 (\< 12) (n = 11)T2 (≥ 12-- \< 16) (n = 17)T3 (≥ 16) (n = 9)ANOVA *p* valueTest for trend *p* valueΔseptal E/e′ ratio (%)4.1 ± 0.3− 12.6 ± 0.4− 19.0 ± 0.40.0070.008 *p* value0.0300.009Age (years)58.6 ± 7.764.4 ± 7.570.6 ± 4.2Duration of diabetes (years)10.5 ± 5.713.1 ± 8.617.9 ± 8.7SBP (mmHg)127.9 ± 10.7132.3 ± 13.4145.1 ± 14.8Heart rate (beats/min)78.2 ± 7.972.1 ± 9.276.0 ± 8.6eGFR (mL/min/1.73 m^2^)84.6 ± 23.376.3 ± 18.965.1 ± 9.4Δhemoglobin (%)5.0 ± 3.56.1 ± 5.16.4 ± 4.6Δseptal E/e′ ratios are mean ± SE. All other values are mean ± SD. Changes in the septal E/e′ ratio were divided according to baseline septal E/e′ ratio tertiles. Results of the Tukey post hoc test compared with T1*E* velocity of early mitral flow; *e′* early peak velocity of septal annulus; *SBP* systolic blood pressure; *eGFR* estimated glomerular filtration rate

Effects of canagliflozin on septal E/e′ ratio in subgroups of the study population {#Sec15}
----------------------------------------------------------------------------------

The septal E/e′ ratio was significantly improved in patients using sulfonylurea (*p* = 0.006) or a DPP-4 inhibitor (*p* = 0.014) at baseline. However, there was no significant difference in patients grouped according to sex, history of hypertension, presence of CVD, insulin use, metformin use, calcium channel blocker use, RAAS inhibitor use, beta blocker use, and diuretic use (Table [6](#Tab6){ref-type="table"}).Table 6Effects of canagliflozin on the septal E/e′ ratio in subgroups of study patientsSubgroupNo. (%)Δseptal E/e′ ratio (%)*p* value for interactionSex Male25 (68)− 5.6 ± 3.10.076 Female12 (32)− 16.9 ± 6.2Hypertension Yes32 (86)− 9.4 ± 3.30.883 No5 (14)− 8.1 ± 7.5History of cardiovascular disease Yes12 (32)− 14.0 ± 3.40.277 No25 (68)− 7.0 ± 3.4Insulin use Yes12 (32)− 2.8 ± 5.70.141 No25 (68)− 12.3 ± 3.4Sulfonylurea use Yes14 (38)− 19.4 ± 4.70.006 No23 (62)− 3.1 ± 3.3Metformin use Yes20 (54)− 10.4 ± 4.40.688 No17 (46)− 7.9 ± 4.0DPP-4 inhibitor use Yes16 (43)− 17.5 ± 4.30.014 No21 (57)− 3.0 ± 3.6Calcium channel blocker use Yes17 (46)− 13.2 ± 4.40.230 No20 (54)− 5.9 ± 4.0RAAS inhibitor use Yes17 (46)− 13.8 ± 3.30.157 No20 (54)− 5.3 ± 4.7Beta blocker use Yes5 (14)− 21.9 ± 4.50.092 No32 (86)− 7.2 ± 3.3Diuretic use Yes4 (11)− 25.7 ± 4.40.053 No33 (89)− 7.2 ± 3.1Values are mean ± SE or no. (%)*DPP* dipeptidyl peptidase-4; *RAAS* renin--angiotensin--aldosterone system

Discussion {#Sec16}
==========

This is the first prospective study of the effects of canagliflozin on left ventricular diastolic function in patients with T2DM who were at high risk of a cardiovascular event. Furthermore, among various parameters that changed through the administration of canagliflozin, only ΔHb significantly correlated with the Δseptal E/e′ ratio. Multiple regression analysis also revealed that ΔHb was an independent predictive factor for the Δseptal E/e′ ratio. On the other hand, canagliflozin caused no exacerbation of autonomic function as assessed by BRS and frequency domain analysis of HRV.

SGLT2 inhibitors were reported to increase Hb, and the involvement of erythropoietin in the mechanism for this increase was reported \[[@CR24]--[@CR26]\]. Inhibited reabsorption of glucose from the proximal tubule was suggested to reduce oxygen consumption in proximal tubule cells, accelerate the recovery of erythropoietin production from interstitial fibroblasts, and thus cause increases in Hb \[[@CR25], [@CR27]\]. Reports showed that erythropoietin had cardioprotective effects \[[@CR28]--[@CR31]\] and that left ventricular diastolic function was improved in patients whose Hb was increased by an erythropoiesis-stimulating agent \[[@CR32], [@CR33]\]. In addition, increases in Hb improve the oxygen supply to tissues, which also results in improved left ventricular diastolic function \[[@CR34], [@CR35]\]. Another important mechanism for the increased Hb values is a reduction in plasma volume due to osmotic diuresis and the natriuretic effect \[[@CR26], [@CR36]\]. Chronic expanded plasma volume is known to increase the burden on the myocardium and trigger cardiac disorders. In patients having heart or renal failure, including those with concomitant diabetes, increases in Hb through decreased plasma volume were reported to correlate with improved mortality \[[@CR37], [@CR38]\]. As SGLT2 inhibitors have been considered to reduce the cardiac workload by decreasing plasma volume \[[@CR39], [@CR40]\], in the present study, decreased plasma volume may have reduced the preload and afterload, resulting in improved left ventricular diastolic function. Such improvement might also be attributed to the simultaneous effects of decreased BP \[[@CR41]\], reduced body weight, less visceral fat \[[@CR42], [@CR43]\], and improvements in endothelial dysfunction \[[@CR44], [@CR45]\], systemic micro-inflammation \[[@CR43]\], cardiac injury \[[@CR46]\], left ventricular hypertrophy, etc. Further investigation is needed to elucidate the mechanism for the improved left ventricular diastolic function resulting from the administration of an SGLT2 inhibitor.

Reductions in BP and plasma volume by an SGLT2 inhibitor diminish the cardiac load, but these agents could possibly have the adverse effect of enhancing sympathetic nervous system activity. Increased sympathetic nervous system activity has important roles in the feedback mechanism of lowered BP and reduced plasma volume; but over the long term, it is known to cause increases in heart load due to an elevated HR and fluid retention and thus becomes a factor in left ventricular diastolic dysfunction. Loop diuretics used for heart failure patients are known to increase sympathetic nervous system activity by reducing plasma volume and thus to adversely affect the long-term outcome \[[@CR47]\]. In this study, canagliflozin did not exacerbate the autonomic function assessed by BRS and frequency domain analysis of HRV. As an SGLT2 inhibitor was reported to improve BRS in an animal study \[[@CR48]\], research on the effects of long-term administration of SGLT2 inhibitors on autonomic function are awaited.

In our subgroup analysis, the improvement in left ventricular diastolic function was significantly greater in those who took sulfonylurea before the start of the study and continued thereafter than in those not given this agent. As sulfonylurea was reported to be involved in left ventricular diastolic dysfunction \[[@CR11]\] and has attenuated cardioprotective effects \[[@CR49]\], it is possible that canagliflozin compensated for the dysfunction caused by the administration of sulfonylurea while reducing the load on the heart. Furthermore, our study patients who were provided with a DPP-4 inhibitor had a significantly greater improvement in their left ventricular diastolic function than those not provided with this drug. A DPP-4 inhibitor is an oral anti-hyperglycemic agent that has many advantages, such as an antiarteriosclerotic effect \[[@CR50]\] and vascular endothelial function-improving effect \[[@CR51]\], but increased hospitalizations due to heart failure have been noted \[[@CR15]\]. We found that combination therapy of a DPP-4 inhibitor with the SGLT2 inhibitor improved left ventricular diastolic function possibly because the SGLT2 inhibitor compensated for some of the concerns regarding DPP-4 inhibitors. In this study, a significant correlation (*r* = − 0.464, *p* = 0.004) was observed between age and improvement in left ventricular diastolic function. Patients administered sulfonylurea (*p* = 0.025) or a DPP-4 inhibitor (*p* = 0.004) were significantly older than those with whom they were compared; thus the results possibly reflect these differences.

Recently, although empagliflozin was reported to have improved left ventricular diastolic function in patients with T2DM with a history of CVD \[[@CR52]\], this is the first report showing the possibility of canagliflozin improving left ventricular diastolic function in patients with T2DM who were mainly grouped according to primary prevention. As the sub-analysis in the CANVAS trial showed a similar inhibitory effect on heart failure-associated hospitalizations between the primary and secondary prevention participants \[[@CR19]\] and canagliflozin significantly suppressed such hospitalizations compared to a DPP-4 inhibitor and a glucagon-like peptide-1 receptor agonist \[[@CR53]\], it is possible that improvement in left ventricular diastolic function was involved in those results. Also, a recent sub-analysis in the EMPA-REG trial indicated that Hb increases were involved in suppression of cardiovascular events independently of lowered plasma glucose and decreased BP, suggesting the involvement of improved left ventricular diastolic function via rises in Hb \[[@CR54]\].

The incidence of heart failure, particularly heart failure with preserved ejection fraction (HFpEF) for which diastolic dysfunction is a major cause, is rapidly increasing globally with aging of the population \[[@CR55], [@CR56]\]. Thus establishment of therapy for such conditions is imperative. However, the outcome of HFpEF cannot be improved even with an angiotensin-converting-enzyme inhibitor, angiotensin receptor blocker, beta blocker, or aldosterone antagonist \[[@CR57]--[@CR60]\], all of which are effective for improving the outcome in heart failure with a reduced ejection fraction (HFrEF) \[[@CR61]\]. A possible reason may be that HFpEF develops due to multiple factors, such as diabetes, hypertension, obesity, and renal dysfunction; optimal treatment of these diseases is likely important in improving left ventricular diastolic function and outcome in HFpEF patients. An SGLT2 inhibitor is likely to be a promising drug in the prevention of HFpEF and improving the outcome of HFpEF by improving left ventricular diastolic function in patients with T2DM. In addition, our results suggested that increases in Hb are involved in improved left ventricular diastolic function and can be used as a predictive marker of such improvement.

This study has three limitations. First, although this was a prospective study, the number of study patients was small and this was uncontrolled observational study. Therefore, larger randomized controlled trials are needed. Second, we could not verify whether the improvement in diastolic function was solely attributable to canagliflozin. Finally, the relationship between the administration of canagliflozin and cardiovascular events could not be verified due to the short research period.

Conclusions {#Sec17}
===========

This study showed for the first time that canagliflozin could improve left ventricular diastolic function in patients with T2DM. The benefit was especially apparent in patients with substantial improvement in Hb values. This result suggests that canagliflozin may have a role in preventing cardiovascular events and heart failure.

Additional file
===============

 {#Sec18}

**Additional file 1: Table S1.** Comparison of echocardiographic findings between baseline and at the end of the 3-months study period in the total population, the primary, and secondary prevention.

T2DM

:   type 2 diabetes mellitus

SGLT

:   sodium-glucose cotransporter

CVD

:   cardiovascular disease

BRS

:   baroreflex sensitivity

HFpEF

:   heart failure with preserved ejection fraction

HFrEF

:   heart failure with reduced ejection fraction
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